8th Mar 2022 20:27
Oxford Cannabinoid Technologies Holdings PLC - pharmaceutical company developing prescription cannabinoid medicines - Says results from recent study show that OCT461201 successfully reduces pain in a pre-clinical animal model of chemotherapy induced peripheral neuropathy induced by paclitaxel, a widely used chemotherapy agent. Two common symptoms of CIPN are pain caused by innocuous stimuli, like light touch and heat or cold. Says in the study, OCT461201 significantly reduced pain from both mechanical allodynia and thermal hyperalgesia compared to untreated animals.
Chief Executive Officer John Lucas says: "Based on previously completed pre-clinical safety experiments, the directors believe the administered dose of OCT461201 could have been increased by over three times. The results of this study demonstrate the opportunities open to OCT461201 in treating a major and common side effect experienced by so many cancer patients and we are more excited than ever to be starting phase 1 clinical trials early next year. These latest results reaffirm the potential of OCT461201 across multiple indications."
Current stock price: 1.43 pence
12-month change: down 71% since May 21, 2021
By Arvind Bhunjun; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
OCTP.L